Compounds > nsc 338720
Page last updated: 2024-08-24

nsc 338720 and Neoplasms

nsc 338720 has been researched along with Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (50.00)18.2507
2000's2 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bowling, K; Chen, TL; Donehower, RC; Grochow, LB; Hartman, NR; O'Reilly, S; Rowinsky, EK; Struck, RF1
Bowman, A; Cummings, J; Dunlop, N; French, R; Jodrell, DI; MacLellan, A; Smyth, JF; Stewart, M1
Bowling, KM; Collins, J; Donehower, RC; Hartman, NR; O'Reilly, S; Rowinsky, EK; Strong, JM1
Alberti, D; Arzomanian, R; Berlin, J; Binger, K; Dresen, A; Feierabend, C; Liu, G; Marnocha, R; Tutsch, KD; Van Ummersen, L; Wilding, G1

Trials

4 trial(s) available for nsc 338720 and Neoplasms

ArticleYear
Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Female; Humans; Male; Middle Aged; Neoplasms; Picolines; Platelet Count

1997
Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.
    British journal of cancer, 1998, Volume: 77, Issue:5

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Picolines; Treatment Failure; Vomiting

1998
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Routes; Drug Administration Schedule; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Picolines

2001
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cerebellar Ataxia; Dizziness; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Picolines

2002